Editas Medicine Out with News, Shares Drop – Baystreet.ca
Nasdaq |
Editas Medicine Out with News, Shares Drop
Baystreet.ca Editas' Chief Scientific Officer Charles Albright declared, "We are encouraged by these results demonstrating efficient targeted integration at the beta-hemoglobin locus with CRISPR/Cas9 and results demonstrating efficient on target editing of adult … Head to Head Comparison: Organovo (ONVO) versus Editas … Zacks' 7 Best Strong Buys for 2018 |
